Point Roberts, WA - March 29, 2011- Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, reports on advances in Cancer Immunotherapy. Bristol-Myers Squibb Company (NYSE:BMY) announced Friday that the U.S. Food and Drug Administration (FDA) approved YERVOY (ipilimumab) 3 mg/kg for the treatment of patients with unresectable (inoperable) or metastatic melanoma.

Bristol-Myers Squibb Company (NYSE:BMY) hit a 52 week high on Friday.

"The approval of YERVOY illustrates the power of harnessing the patient's own immune system to combat cancer,” stated Jim Joyce, CEO of Aethlon Medical. "With the recent approval of PROVENGE from Dendreon, the cancer immunotherapy era seems to be well underway.

Read more: Biotech/Pharma Snapshot; Advances in Cancer Immunotherapy; (OTCBB: AEMD), (NYSE: BMY), Dendreon...

Point Roberts, WA. March 25, 2011  Investorideas.com, a leader in sector research including biotech and biodefense stocks, presents an interview with Jim Joyce, CEO of Aethlon Medical (OTCBB: AEMD).

InvestorIdeas: What opportunities exist for small organizations that want to participate in the emerging biodefense industry?

Jim Joyce, CEO of Aethlon Medical ( OTCBB: AEMD )

Multiple opportunities have recently surfaced for small organizations with innovative countermeasures against bioterror threats, and more are expected in the near future.

Read more: Emerging Opportunities in Biodefense; An interview with Aethlon Medical (OTCBB: AEMD) CEO, Jim...

As a second batch of East European hackers were charged on Thursday - this time in the US - with siphoning money from online bank account users using the Zeus trojan, Secure Browsing Service specialist Trusteer says there are other Zeus cybercrime gangs operating elsewhere in the world. Trusteer's comments come in the wake of a rash of arrests in the UK on Wednesday, which culminated in formal charges being laid against 11 Eastern Europeans from all walks of life. In the US, meanwhile, Thursday also saw charges laid against 70 further East Europeans, who allegedly used Zeus to steal at least $3 million from US bank accounts.

“The recent arrests in the US and the UK indicate that financial fraud is not the business of individuals,” says said Mickey Boodaei, Trusteer's CEO. “Behind these operations you can find groups of people which in many cases operate for larger organized crime groups.

Read more: Seventy hackers charged for $3m online bank fraud

Imperva and Qualys Partner To Help Enterprises Protect Against Malicious Attacks on Web Applications

Savvis Provides Integrated Offering To Customers REDWOOD SHORES, CALIF., –March 1, 2010 – Qualys, the leading provider of on demand IT security risk and compliance management solutions, and Imperva, the data security leader, today announced the integration of Qualys’  QualysGuard® Web Application Scanning with Imperva’s SecureSphere Web Application Firewall (WAF). This combination gives enterprises an ability to deploy a comprehensive security strategy that delivers powerful protection for business-critical Web applications. Savvis, Inc. (Nasdaq: SVVS), a global leader in outsourced internet infrastructure services for enterprises, will provide the Qualys-Imperva integrated solution as part of its hosting and Savvis Symphony cloud infrastructure solutions for enterprises..

Read more: Savvis Inc ( SVVS )

ArcSight Reports 25% Year-Over-Year Growth for Fiscal First Quarter Ended July 31, 2009

ArcSight, Inc. (NASDAQ: ARST), a leading global provider of security and compliance management solutions that protect enterprises and government agencies, today announced financial results for its fiscal first quarter ended July 31, 2009.

For the first quarter of fiscal 2010, ArcSight reported total revenues of $34.6 million compared to total revenues of $27.7 million reported in the first quarter of fiscal 2009. Net income on a GAAP basis for the first quarter of fiscal 2010 was $1.0 million, or $0.03 per diluted share, including $222,000 in amortization of intangible assets and $1.9 million in stock-based compensation expense. This compares to a GAAP net loss of $1.3 million, or $(0.04) per diluted share, reported in the first quarter of fiscal 2009, including $211,000 in amortization of intangible assets and $1.4 million in stock-based compensation expense.

Read more: ArcSight Inc ( ARST )